相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular Architecture and Assembly of the Eukaryotic Proteasome
Robert J. Tomko et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 82 (2013)
Expression of the BRCA1 complex member BRE predicts disease free survival in breast cancer
Sylvie M. Noordermeer et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts
Samantha A. Simpkins et al.
JOURNAL OF PATHOLOGY (2012)
Targeting the Ubiquitin plus Proteasome System in Solid Tumors
James J. Driscoll et al.
SEMINARS IN HEMATOLOGY (2012)
Predictive Factors for Local Recurrence in Breast Cancer
Femke van der Leij et al.
SEMINARS IN RADIATION ONCOLOGY (2012)
Antiproteasomal agents in rectal cancer
Claudius Conrad et al.
ANTI-CANCER DRUGS (2011)
A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer
Dalia ELFadl et al.
BREAST (2011)
Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer
Sampoorna Satheesha et al.
MOLECULAR CANCER (2011)
Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer
Caroline M. Woolston et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells
B. M. Madhok et al.
BRITISH JOURNAL OF CANCER (2010)
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
K. David Voduc et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer
Zhi Hu et al.
BREAST CANCER RESEARCH (2010)
The vital link between the ubiquitin-proteasome pathway and DNA repair: Impact on cancer therapy
Akira Motegi et al.
CANCER LETTERS (2009)
PHASE I TRIAL USING PROTEASOME INHIBITOR BORTEZOMIB AND CONCURRENT TEMOZOLOMIDE AND RADIOTHERAPY FOR CENTRAL NERVOUS SYSTEM MALIGNANCIES
Gregory J. Kubicek et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy
Paul L. Nguyen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group
Marianne Kyndi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy
Oliver Riesterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer
Karin Soderlund et al.
RADIOTHERAPY AND ONCOLOGY (2007)
The proteasome: A worthwhile target for the treatment of solid tumours?
Amalia Milano et al.
EUROPEAN JOURNAL OF CANCER (2007)
Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma
C Van Waes et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Altering protein turnover in tumor cells: New opportunities for anti-cancer therapies
F Demarchi et al.
DRUG RESISTANCE UPDATES (2005)
Perspectives for combination therapy to overcome drug-resistant multiple myeloma
L Catley et al.
DRUG RESISTANCE UPDATES (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
